Clinical Trial Update: Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy [Phase 2]

View source ↗

Summary

Open-label extension of EDG-5506 in Becker Muscular Dystrophy. The Phase 2 trial is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Becker Muscular Dystrophy

Drugs mentioned

• EDG-5506 (EDG-5506)

Snippet

Sponsor: Edgewise Therapeutics, Inc. | Conditions: Becker Muscular Dystrophy | Phase 2 | Status: ENROLLING_BY_INVITATION